Centessa Pharmaceuticals Plc ADR (CNTA)

$39.66 +0.13 (0.33%)
Market Cap 6.13B
Revenue (ttm) 15.00M
Net Income (ttm) -197.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,316.87%
Debt to Equity Ratio 0.21
Volume 3,773,800
Avg Vol 2,850,732
Day's Range N/A - N/A
Shares Out 154.57M
Stochastic %K 78%
Beta 1.25
Analysts Sell
Price Target $40.55

Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive...

Industry: Biotechnology
Sector: Healthcare
Address:
1 Ashley Road, 3rd Floor, Altrincham, United Kingdom
DonCorleone77
DonCorleone77 Apr. 13 at 4:48 AM
$CNTA Centessa downgraded to Hold from Buy at Truist Truist analyst Danielle Brill downgraded Centessa (CNTA) to Hold from Buy with a $38 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable contingent value right worth up to $9 per share.
0 · Reply
CapitalMonk
CapitalMonk Apr. 2 at 3:30 PM
$CNTA Price: $39.67 (-0.46%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±6.06% RSI: 78.5 | Momentum: Strong Momentum Volume: -60.0% vs avg Volatility: 10.45% Support: $25.06 | Resistance: $40.26 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
WycklyTrader
WycklyTrader Apr. 2 at 4:17 AM
KALV / PHVS potential big pharma acquisitions for hereditary angioedema (HAE) treatments. $APLS $DAWN $FOLD $EXAS $CNTA . BEP energy play.
0 · Reply
Spicy_Trade
Spicy_Trade Apr. 2 at 4:09 AM
$CNTA Stock analysis https://youtu.be/DKJlY-cIfwo?si=d8brZd4Aq_Muj25T
0 · Reply
ZacksResearch
ZacksResearch Apr. 1 at 4:00 PM
$LLY just made a $7.8B move — and it’s not about obesity 👀 Lilly is acquiring $CNTA for $6.3B upfront (up to $7.8B with CVRs), adding a pipeline of OX2R agonists led by cleminorexton in mid-stage trials for narcolepsy and IH — a clear push to diversify beyond its GLP-1 dominance 💊 Centessa stock surged 44% on the news, while Lilly gained ~4%, signaling strong market approval of the strategy. Latest LLY news here 👉 https://www.zacks.com/stock/quote/LLY?cid=sm-stocktwits-0-quote_overview-oc-37620&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_37620
0 · Reply
Stocks_and_Stacks
Stocks_and_Stacks Apr. 1 at 1:59 AM
🚀 Bulls in full charge today! 🐂🔥 Huge congrats to everyone riding these top movers on March 31: $FLY +20% – Space stocks lifting off on SpaceX IPO buzz and sector momentum! $APLS +135% – Biogen acquiring Apellis for $5.6B in a blockbuster immunology deal! $CNTA +44% – Eli Lilly snapping up Centessa for up to $7.8B to boost sleep-wake disorder pipeline! Epic green day – keep stacking those gains, bulls! 💪📈 Who else is celebrating? #TopMovers #BullMarket #Stocks
1 · Reply
topstockalerts
topstockalerts Mar. 31 at 11:18 PM
Top Gainers PT2 $KIDZ $GVH $WSHP $CNTA $HKIT
0 · Reply
LibertarianTreehugger
LibertarianTreehugger Mar. 31 at 8:50 PM
Eli Lilly Just Made a $7 Billion Bet on the Future of Sleep: https://www.smartinvestornews.com/all-articles/eli-lilly-just-made-a-7-billion-bet-on-the-future-of-sleep $LLY $CNTA
0 · Reply
Selfmade_millionaire
Selfmade_millionaire Mar. 31 at 8:45 PM
$CNTA short this sh1t
1 · Reply
RunnerSignals
RunnerSignals Mar. 31 at 8:36 PM
52 week highs breakout stocks ​$APLS $CNTA $UNIT $BTE $PFE breakouts show selective accumulation RSI elevated yet volume confirms institutions adding not distributing
0 · Reply
Latest News on CNTA
Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly

Mar 31, 2026, 7:43 PM EDT - 19 days ago

Nxera Pharma's Partner Centessa Pharmaceuticals to be Acquired by Lilly

LLY

Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs

Mar 31, 2026, 12:24 PM EDT - 19 days ago

Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs

LLY

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs

Mar 31, 2026, 10:46 AM EDT - 19 days ago

Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs

LLY

Why Eli Lilly Is Buying Centessa for $7.8 Billion

Mar 31, 2026, 10:27 AM EDT - 19 days ago

Why Eli Lilly Is Buying Centessa for $7.8 Billion

LLY

Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion

Mar 31, 2026, 7:18 AM EDT - 19 days ago

Eli Lilly to Buy Centessa Pharmaceuticals for Initial $6.3 Billion

LLY

Eli Lilly to buy Centessa Pharma in $6.3 billion deal

Mar 31, 2026, 6:53 AM EDT - 19 days ago

Eli Lilly to buy Centessa Pharma in $6.3 billion deal

LLY

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Mar 31, 2026, 6:45 AM EDT - 19 days ago

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

LLY

Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals

Mar 5, 2026, 3:03 AM EST - 6 weeks ago

Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals

Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals

Feb 12, 2026, 3:45 AM EST - 2 months ago

Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Feb 3, 2026, 8:00 AM EST - 2 months ago

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

Jan 14, 2026, 5:00 PM EST - 3 months ago

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa

Jan 13, 2026, 3:09 AM EST - 3 months ago

Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Dec 11, 2025, 7:00 AM EST - 4 months ago

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

Nov 11, 2025, 8:40 PM EST - 5 months ago

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

Nov 11, 2025, 4:00 PM EST - 5 months ago

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

Nov 5, 2025, 7:00 AM EST - 5 months ago

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 7:00 AM EDT - 8 months ago

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

Aug 12, 2025, 7:00 AM EDT - 8 months ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

Jul 4, 2025, 3:00 AM EDT - 10 months ago

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

Jun 16, 2025, 9:00 AM EDT - 10 months ago

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

Mar 6, 2025, 4:14 PM EST - 1 year ago

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

Jan 8, 2025, 7:05 AM EST - 1 year ago

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Nov 12, 2024, 7:00 AM EST - 1 year ago

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Sep 26, 2024, 6:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Sep 12, 2024, 10:34 PM EDT - 1 year ago

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Sep 11, 2024, 4:04 PM EDT - 1 year ago

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Sep 11, 2024, 6:52 AM EDT - 1 year ago

Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 21, 2024, 8:00 AM EDT - 1 year ago

Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

Jun 10, 2024, 7:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

May 13, 2024, 4:10 PM EDT - 2 years ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

Apr 23, 2024, 9:36 PM EDT - 2 years ago

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

Apr 23, 2024, 4:17 PM EDT - 2 years ago

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

Apr 22, 2024, 7:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

Mar 28, 2024, 4:28 PM EDT - 2 years ago

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and

Feb 9, 2024, 7:00 AM EST - 2 years ago

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and

Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference

Dec 13, 2023, 8:00 AM EST - 2 years ago

Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

Dec 10, 2023, 12:05 PM EST - 2 years ago

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

Nov 13, 2023, 4:05 PM EST - 2 years ago

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting

Nov 2, 2023, 9:09 AM EDT - 2 years ago

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

Aug 23, 2023, 5:08 PM EDT - 2 years ago

Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

DonCorleone77
DonCorleone77 Apr. 13 at 4:48 AM
$CNTA Centessa downgraded to Hold from Buy at Truist Truist analyst Danielle Brill downgraded Centessa (CNTA) to Hold from Buy with a $38 price target after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable contingent value right worth up to $9 per share.
0 · Reply
CapitalMonk
CapitalMonk Apr. 2 at 3:30 PM
$CNTA Price: $39.67 (-0.46%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±6.06% RSI: 78.5 | Momentum: Strong Momentum Volume: -60.0% vs avg Volatility: 10.45% Support: $25.06 | Resistance: $40.26 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
WycklyTrader
WycklyTrader Apr. 2 at 4:17 AM
KALV / PHVS potential big pharma acquisitions for hereditary angioedema (HAE) treatments. $APLS $DAWN $FOLD $EXAS $CNTA . BEP energy play.
0 · Reply
Spicy_Trade
Spicy_Trade Apr. 2 at 4:09 AM
$CNTA Stock analysis https://youtu.be/DKJlY-cIfwo?si=d8brZd4Aq_Muj25T
0 · Reply
ZacksResearch
ZacksResearch Apr. 1 at 4:00 PM
$LLY just made a $7.8B move — and it’s not about obesity 👀 Lilly is acquiring $CNTA for $6.3B upfront (up to $7.8B with CVRs), adding a pipeline of OX2R agonists led by cleminorexton in mid-stage trials for narcolepsy and IH — a clear push to diversify beyond its GLP-1 dominance 💊 Centessa stock surged 44% on the news, while Lilly gained ~4%, signaling strong market approval of the strategy. Latest LLY news here 👉 https://www.zacks.com/stock/quote/LLY?cid=sm-stocktwits-0-quote_overview-oc-37620&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_37620
0 · Reply
Stocks_and_Stacks
Stocks_and_Stacks Apr. 1 at 1:59 AM
🚀 Bulls in full charge today! 🐂🔥 Huge congrats to everyone riding these top movers on March 31: $FLY +20% – Space stocks lifting off on SpaceX IPO buzz and sector momentum! $APLS +135% – Biogen acquiring Apellis for $5.6B in a blockbuster immunology deal! $CNTA +44% – Eli Lilly snapping up Centessa for up to $7.8B to boost sleep-wake disorder pipeline! Epic green day – keep stacking those gains, bulls! 💪📈 Who else is celebrating? #TopMovers #BullMarket #Stocks
1 · Reply
topstockalerts
topstockalerts Mar. 31 at 11:18 PM
Top Gainers PT2 $KIDZ $GVH $WSHP $CNTA $HKIT
0 · Reply
LibertarianTreehugger
LibertarianTreehugger Mar. 31 at 8:50 PM
Eli Lilly Just Made a $7 Billion Bet on the Future of Sleep: https://www.smartinvestornews.com/all-articles/eli-lilly-just-made-a-7-billion-bet-on-the-future-of-sleep $LLY $CNTA
0 · Reply
Selfmade_millionaire
Selfmade_millionaire Mar. 31 at 8:45 PM
$CNTA short this sh1t
1 · Reply
RunnerSignals
RunnerSignals Mar. 31 at 8:36 PM
52 week highs breakout stocks ​$APLS $CNTA $UNIT $BTE $PFE breakouts show selective accumulation RSI elevated yet volume confirms institutions adding not distributing
0 · Reply
topstockalerts
topstockalerts Mar. 31 at 8:03 PM
Todays Top Gainers PT2 $KIDZ $GVH $CNTA $WSHP $HKIT
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 31 at 6:55 PM
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes $ALKS $LLY $CNTA https://stocktwits.com/news/equity/markets/alks-stock-surges-on-lilly-centessa-buyout-igniting-sleep-pipeline-hopes/cZE55YcRIVr
0 · Reply
M17K
M17K Mar. 31 at 6:54 PM
$SLS 👀 multi-billion dollar buyouts are so hot right now $APLS $CNTA
0 · Reply
topstockalerts
topstockalerts Mar. 31 at 6:16 PM
Top Gainers PT2 $GV $CNTA $WSHP $NPT $CRMU
0 · Reply
Sompirate101
Sompirate101 Mar. 31 at 5:29 PM
$CNTA someone explain to that volume and why it's not moving up and down ?
0 · Reply
topstockalerts
topstockalerts Mar. 31 at 4:38 PM
Midday Top Gainers PT2 $CNTA $WSHP $VRAX $NPT $OXBR
0 · Reply
TalkMarkets
TalkMarkets Mar. 31 at 4:18 PM
#Dow Eyes Worst Month Since 2022 Despite Last Minute Flourish $CNTA $FDS $CEG $DJI $SPX https://talkmarkets.com/article/04164255-0666-4bc6-beb2-5ecb9fa7ec22
0 · Reply
DragonTiger
DragonTiger Mar. 31 at 3:58 PM
$NVAX $CNTA is taken out by Lily wit $4B, no revenue! Yo parasite mfker criminal JJ Josh should be arrested immediately!
0 · Reply
lebranjames
lebranjames Mar. 31 at 3:40 PM
$MLTX according to chat, this is the #1 ranked biotech as a take over target by big pharma. Valuation is very cheap here. If $CNTA can get bought out for 9b then what’s this worth?!
0 · Reply
nobodyyk
nobodyyk Mar. 31 at 3:35 PM
$CNTA $IXHL $LLY good job CNTA, this is how it’s done Joel. They know how to manage their company. Had you known how to turn a company, $RMD and others would have had a bid war for you.
1 · Reply
Fi0na__B
Fi0na__B Mar. 31 at 3:35 PM
$CNTA Great Trade!
0 · Reply
topstockalerts
topstockalerts Mar. 31 at 3:11 PM
Top Gainers PT2 $OXBR $CNTA $GV $POLA $VRAX
1 · Reply